Compare DSGR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSGR | ORIC |
|---|---|---|
| Founded | 1952 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1995 | 2020 |
| Metric | DSGR | ORIC |
|---|---|---|
| Price | $34.66 | $13.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $35.00 | $19.73 |
| AVG Volume (30 Days) | 205.4K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 212.50 | 19.67 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,980,023,000.00 | N/A |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $3.79 | N/A |
| P/E Ratio | $182.42 | ★ N/A |
| Revenue Growth | ★ 9.75 | N/A |
| 52 Week Low | $19.02 | $7.23 |
| 52 Week High | $35.06 | $14.93 |
| Indicator | DSGR | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 68.46 | 49.87 |
| Support Level | $34.54 | $10.17 |
| Resistance Level | $34.85 | $14.27 |
| Average True Range (ATR) | 0.13 | 0.63 |
| MACD | -0.19 | -0.23 |
| Stochastic Oscillator | 34.78 | 14.80 |
Distribution Solutions Group Inc is a specialty distribution company providing value-added distribution solutions to the maintenance, repair and operations (MRO), original equipment manufacturer (OEM) and industrial technology markets. The company operates through four reportable segments: Lawson, TestEquity, Gexpro Services and Canada Branch Division. Lawson distributes specialty products and services to the industrial, commercial, institutional and government MRO marketplace. TestEquity, which generates maximum revenue, distributes test and measurement equipment and solutions, industrial and electronic production supplies and vendor managed inventory programs. Gexpro Services is a supply chain solutions provider. The company generates majority of its revenue from United States.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.